-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Business and Investments
Latest From Business and Investments
Scientific American Worldview Scorecard Correlates with International Investment
Biotechnology innovation requires investment, and the Scientific American Worldview Scorecard can predict where investment goes. A recent analysis indicates that the ranking of countries in this Scorecard correlates with global investment. As a result, the Worldview Scorecard provides a valuable tool for any country interested in increasing its appeal to biotechnology investors. In short, the Worldview Scorecard uses a wide collection of data – compiled and analyzed by Yali Friedman – that generates a metric Read More >
SBIR Reauthorization Moves Forward
NIH has reissued its Small Business Innovation Research (SBIR) Omnibus Grant Solicitation announcement, which states that small businesses that are majority-owned by multiple venture capital operating companies are eligible to apply for (1) these SBIR grants and (2) any other NIH SBIR funding opportunities announced after January 28, 2013. The NIH grant solicitation announcement can be found here. With this re-issuance, small businesses that are majority-owned by multiple venture capital operating companies (VCOCs), hedge funds Read More >
BIO Convention Post-Con, Plus a Look Ahead
Last month, the biopharma community gathered for the industry’s largest event, the BIO International Convention. We hope the event was successful for everyone who attended. We know it was a busy time for folks, especially based on the numbers from the Partnering System! Here is a quick recap: BIO One-on-One Partnering Stats for BIO2013 A total of 25,537 One-on-One Partnering meetings were scheduled at the event, officially beating last year’s record! Partnering Meeting Requests increased Read More >
Only 12% of Public Biotechs are Profitable
Of the 286 biotech companies trading on public exchanges today, 241 focus on drug development, a slight drop in numbers from last year.* Of these 241 in the biopharmaceutical space, only 28 (12%) had both a product on the market and positive net income for FY 2012. This is about the same as the 13% reported last year, but different companies populate the list. Unlike our last report (May 2012), when acquisitions of profitable companies Read More >
Breakthrough Designations Reach 13
One of the outcomes of the 2012 Food and Drug Administration Safety and Innovation Act (FDASIA) was the creation of the “Breakthrough Therapy” designation. The new law allows FDA to grant a Breakthrough Therapy designation to drugs showing early clinical promise for serious or life-threatening conditions, thereby expediting both the development and the review of these drugs. As of today, 13 designations have been granted according to a search of the BioMedTracker database (see table Read More >
